文献速递肝病

贝特类药物治疗瘙痒(FITCH):纤维化性胆管病中的双盲、随机、安慰剂对照试验

Fibrates for Itch (FITCH) in Fibrosing Cholangiopathies: A Double-Blind, Randomized, Placebo-Controlled Trial.
PubMed 文献 · Gastroenterology · 2020-10-05

FITCH试验纳入74例中重度瘙痒的PSC、PBC或SSC患者,随机接受每日一次贝扎贝特400 mg或安慰剂治疗21天。贝扎贝特组45%达到主要终点(瘙痒VAS下降≥50%),安慰剂组为11%(P = .003);贝扎贝特还改善早晚瘙痒强度和5D-Itch问卷,并降低血清碱性磷酸酶35%。

要点

  • 贝扎贝特400 mg每日一次治疗21天,45%患者瘙痒VAS下降≥50%,安慰剂组为11%(P = .003)。
  • 贝扎贝特降低早晨(P = .01)和晚间(P = .007)瘙痒VAS强度,并改善5D-Itch问卷(P = .002)。
  • 贝扎贝特降低血清碱性磷酸酶35%(P = .03 vs 安慰剂),与瘙痒改善相关(VAS,P = .01)。

核心结论

  • 在PSC和PBC患者中,贝扎贝特在改善中重度瘙痒方面优于安慰剂。

研究设计与样本

  • 研究者发起的双盲、随机、安慰剂对照试验,2016年至2019年招募因PSC、PBC或SSC导致中重度瘙痒(VAS≥5/10)的患者。
  • 患者每日一次接受贝扎贝特400 mg或安慰剂治疗21天,主要终点为瘙痒VAS下降≥50%(意向性分析)。
  • 共随机74例患者,70例完成试验(95%;44例PSC、24例PBC、2例SSC)。

主要发现

  • 主要终点:贝扎贝特组45%(PSC 41%、PBC 55%)达到瘙痒VAS下降≥50%,安慰剂组为11%(P = .003)。
  • 次要终点:贝扎贝特降低早晨瘙痒VAS强度(P = .01 vs 安慰剂)和晚间瘙痒VAS强度(P = .007),并改善经验证的5D-Itch问卷(P = .002 vs 安慰剂)。
  • 贝扎贝特降低血清碱性磷酸酶35%(P = .03 vs 安慰剂),与瘙痒改善相关(VAS,P = .01),提示胆道损伤减少。
  • 血清胆汁酸和自分泌运动因子活性保持不变;血清肌酐水平有轻度升高趋势(贝扎贝特组3%,安慰剂组5%,P = .14)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Pruritus may seriously impair quality of life in patients with cholestatic diseases such as primary or secondary sclerosing cholangitis (PSC, SSC) and primary biliary cholangitis (PBC). Pharmacologic strategies show limited efficacy and can provoke serious side effects. We hypothesized that bezafibrate, a broad peroxisome proliferator-activated receptor (PPAR) agonist, relieves cholestasis-associated itch by alleviating hepatobiliary injury. The aim of this investigator-initiated FITCH trial (Fibrates for cholestatic ITCH) was to assess effects of bezafibrate on pruritus in patients with PSC, PBC, and SSC. METHODS: Patients with moderate to severe pruritus (≥5 of 10 on visual analog scale [VAS]) due to PSC, PBC, or SSC were recruited for this double-blind, randomized, placebo-controlled trial between 2016 and 2019. Patients received once-daily bezafibrate (400 mg) or placebo for 21 days. The primary end point was ≥50% reduction of pruritus (VAS; intention-to-treat). RESULTS: Of 74 randomized patients, 70 completed the trial (95%; 44 PSC, 24 PBC, 2 SSC). For the primary end point, bezafibrate led in 45% (41% PSC, 55% PBC) and placebo in 11% to ≥50% reduction of severe or moderate pruritus (P = .003). For secondary end points, bezafibrate reduced morning (P = .01 vs placebo) and evening (P = .007) intensity of pruritus (VAS) and improved the validated 5D-Itch questionnaire (P = .002 vs placebo). Bezafibrate also reduced serum alkaline phosphatase (-35%, P = .03 vs placebo) correlating with improved pruritus (VAS, P = .01) suggesting reduced biliary damage. Serum bile acids and autotaxin activity remained unchanged. Serum creatinine levels tended to mildly increase (3% bezafibrate, 5% placebo, P = .14). CONCLUSIONS: Bezafibrate is superior to placebo in improving moderate to severe pruritus in patients with PSC and PBC. TRIAL REGISTRATION: Netherlands Trial Register, ID: NTR5436 (August 3, 2015), ClinicalTrials.gov ID: NCT02701166 (March 2, 2016).

来源:Gastroenterology,查看原文。版权归原作者所有。

引用

  1. de Vries E, Bolier R, Goet J, et al. Fibrates for Itch (FITCH) in Fibrosing Cholangiopathies: A Double-Blind, Randomized, Placebo-Controlled Trial. Gastroenterology. 2020. PMID: 33031833. doi:10.1053/j.gastro.2020.10.001

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。